For income-focused investors, a dividend stock's true value lies not just in the quarterly check but in the underlying business's ability to sustain and grow those payments over decades. Two companies that consistently meet this bar are Procter & Gamble (NYSE: PG) and Stryker (NYSE: SYK). Their latest earnings reports underscore why they remain compelling long-term holdings.
Procter & Gamble: Cash Flow Powerhouse
Procter & Gamble's strength is rooted in its portfolio of everyday essentials—Tide, Pampers, and Crest—that generate repeat purchases regardless of economic conditions. The company's fiscal first-quarter results, released on October 22, highlighted this resilience. Sales rose 4% to approximately $23.3 billion, with organic sales also up 4%. Core earnings per share reached $2.00, a 1% increase.
For dividend investors, the critical metric is cash flow. P&G generated $5.8 billion in operating cash flow during the quarter, comfortably covering its $2.6 billion in dividend payments. This cash generation supports an impressive track record: the company has increased its dividend for 70 consecutive years. The current quarterly dividend of $1.0885 per share translates to an annualized $4.354, and reinvesting those payments can gradually amplify future increases.
However, challenges persist. P&G now expects a $1.4 billion after-tax commodity cost headwind in fiscal 2027, illustrating how inflation can pressure even the strongest brands. Despite this, management still anticipates distributing over $10 billion in dividends this fiscal year. The investment case hinges on the company's ability to keep generating cash through difficult conditions, with the purchase price remaining a key determinant of total returns.
Stryker: Growth Engine for Future Dividends
Stryker offers a different proposition: an expanding earnings base that could support larger shareholder payments over time. Its implants, surgical equipment, and Mako robotic technology tap into enduring demand for advanced medical care and improved mobility. In its fiscal second quarter of 2026, Stryker reported revenue of $6.6 billion, up 9.4% year-over-year, with organic sales climbing 9% on higher unit volume. Adjusted earnings per share jumped 17.9% to $3.69, while adjusted operating margin expanded 170 basis points to 27.4%.
The company's quarterly dividend stands at $0.88 per share, or $3.52 annualized. Against management's full-year adjusted earnings guidance of $14.95 to $15.10 per share, the payout ratio is roughly 23.4% to 23.5%. While adjusted earnings differ from available cash, the relatively low ratio suggests ample room to balance dividend growth with reinvestment in the business.
Investors will get the next financial update on October 29. Risks include hospital budget constraints, product quality issues, and acquisition execution. Nevertheless, Stryker's combination of volume growth and improving profitability makes it an appealing candidate for patient investors seeking long-term dividend growth.
This article is for informational purposes only and does not constitute financial advice.
